期刊文献+

立普妥治疗急性冠脉综合征的多效性分析 被引量:2

下载PDF
导出
摘要 目的本研究旨在观察急性冠脉综合征患者坚持服用他汀类药物立普妥的疗效并观察立普妥的多效性作用。方法选取出院后门诊随访及再次入院的ACS患者385例,其中179例坚持服用立普妥,206例未服用任何他汀类药物,2组均常规服用扩冠抗血小板及ACEI药物;随访6个月观察2组死亡率、ACS再发等情况的差异。结果坚持服用立普妥药物组死亡率、ACS再发等情况均不同于未服用他汀类药物组,两者有显著差异。结论对急性冠脉综合征(ACS)患者治疗用立普妥时,除可调整血脂水平外,还具有抗炎、稳定斑块等其它功能。
作者 李守凯
出处 《中外医疗》 2010年第36期125-126,共2页 China & Foreign Medical Treatment
  • 相关文献

参考文献4

  • 1杨莉莉,赵宇.C反应蛋白水平与急性冠状动脉综合征预后的关系[J].医学研究杂志,2006,35(6):66-67. 被引量:5
  • 2金凤表,侯瑞田,蒋宝琦,吴彦.阿托伐他汀的非调脂作用[J].心血管病学进展,2003,24(2):125-127. 被引量:22
  • 3Arampatzics CA,Lemos PA,Tanabe K,et al.Effectiveness of sirolimus-eluting stent for treatment of left main coronary arterydisease[J].J cardio,1 2003,92(6):327~329.
  • 4Nissen SE,Tuzcu EM,Schoenhagen P,et al.For the REVERSAL lnves-tigators effect of intensive compared with moderate lipidlowering therapy on progression ot coronary atherosclerosis a randomized controlled trial[J].JAMA,2004,291:1071~1080.

二级参考文献16

  • 1[1]Wilcox LJ, Barrett PH, Huff MW. Differential regulation of apolipoprotein B secretion from HepG2 cells by two HMG-CoA reductase inhibitors, atorvastatin and simvastatin[J]. J Lipid Res, 1999,40(6) :1078-1089.
  • 2[2]Elkin RG, Yan Z ,Zhong Y, et al. Select 3-hydroxy-3-methylglutary 1-coenzyme A reductase inhibitors vary in their ability to reduce egg yolk cholesterol levels in laying hens through alteration of hepatic cholesterol biosynthesis and plasma VLDL composition[J].J Nutr, 1999,129(5) :1010-1019.
  • 3[3]Alfon J, Guasch JF, Berrozpe M,et al. Nitric oxide synthase Ⅱ(NOS Ⅱ ) gene expreuion correlates with atherosclerotic intimal thickening. Preventive effects of HMG-CoA reductase inhibitors[J]. Atherosclerosis, 1999,145 (2) :325 -331.
  • 4[4]Wagner AH, Kohler T, Ruckschloss U,et al. Improvement of nitric oxide-dependent vasodilatation by HMG-CoA reductase inhibitors through attenuation of endothelial auperoxide anion formation [J]. Arterioscler Thromb Vasc Biol,2000,20( 1 ) :61-69.
  • 5[5]Bustos C, Hernandez-Presa MA, Orteqo M,et al. HMG-CoA reductase inhibition by atorvastatin reduces neointimal inflammation in a rabbit model of atherosclerosis[ J ]. J Am Coll Cardiol, 1998,32 (7) :2057-2064.
  • 6[6]Park HJ, Galper JB. 3-Hydroxy-3-methylglutary1 CoA reductase inhibitors upregulate transforming growth factor-beta signaling in cultured heart cells via inhibition of geranylgeranylation of RhoA GTPase. Proc Natl Acad Sci USA [ J ].1999,96(20) :11525-11530.
  • 7[7]Strandberg TE,Vanhanen H, Tikkanen MJ. Effect of statins on C-reactive protein in patients with coronary heart disease[J]. Lancet, 1999,353:118-119.
  • 8[8]Tesfamariam B, Frohlich BH, Gregg RE. Differential effects of pravastatin,simvastatin, and atorvastatin on Ca2 + release and vascular reactivity[J]. J Cardiovasc Pharmacol, 1999,34( 1 ) :95-101.
  • 9[9]Niekenig G, Baumer AT, Temur Y, et al. Statin-sensitive dysregulated AT1 receptor function and density in hypercholesterolemic men[J].Circulation. 1999.100(21 ) :2131-2134.
  • 10[10]Alfon J, Pueyo Palazon C, Royo T,et al. Effects of statins in thrombosis and aortic lesion development in a dyslipemic rabbit model[J]. Thromb Haemost,1999,81 (5) :822-827.

共引文献24

同被引文献25

引证文献2

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部